CURRENT REPORT FOR ISSUERS SUBJECT TO THE

1934 ACT REPORTING REQUIREMENTS

FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act

Date of Report (Date of Earliest Event Reported): ~~July~~June 1311, ~~2012~~2013

Radient Pharmaceuticals Corporation

(Exact name of registrant as specified in its charter)

Delaware	~~001-16695~~	33001-~~0413161~~16695	33-0413161
(State or other
(State or other Jurisdiction of Incorporation)		(Commission File Number)	(IRS Employer Identification No.)
jurisdiction of	(Commission File Number)	(IRS Employer Identification No.)
incorporation)

2492 Walnut Avenue, Suite 100, Tustin, California, 92780-7039

(Address of principal executive offices (zip code))

714-505-4461

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Section 1 –- Registrant’s Business and Operations

Item 1.01 –- Entry into Material Definitive Agreements

On ~~July~~June ~~13,~~6th ~~2012~~2013, we entered into a 5-year license agreement ~~with~~between ~~Global~~AMDL ~~Cancer~~ Diagnostics, Inc. (~~"GCDx"~~“ADI”), ina ~~order~~division towithin ~~commercialize certain of~~ our ~~intellectual~~ ~~property~~company, inand ~~the~~Uni ~~form~~Pharma ofCo., Ltd. a ~~Lung~~Taipei ~~Cancer~~Taiwan ~~test;~~limited ~~the~~liability ~~intellectual~~company ~~property~~(“UNI”) atthat ~~issue~~provides isUNI ~~specified~~with ina ~~the~~5-year ~~Agreement~~exclusive ~~and~~license ~~is herein~~(subject ~~referred~~ to asautomatic ~~the~~renewal ~~Licensed~~for ~~Products.~~an ~~Under~~additional ~~the~~5 ~~Agreement,~~years) ~~GCDx~~to ~~will~~RXPC’s beOnko-Sure® ~~the~~(formerly ~~only~~called ~~company~~DR-70 ~~offering~~cancer ablood test ~~specific~~kits to(the ~~lung cancer~~“Tests”), ~~but~~procedures, ~~will~~analyses, ~~not~~data, ~~make~~know how, ~~use~~manufacturing, ofmanufacturing orprocesses, ~~sell~~components, ~~any~~trademarks ofand ~~our~~intellectual ~~other~~property. ~~tests~~Pursuant ~~using~~to the ~~DR-70~~terms ~~reagents.~~of ~~GCDx~~the ~~will~~Agreement, ~~pay~~the antotal ~~upfront~~ license fee of shall be US$~~200~~500,000, ~~for~~$100,000 ~~the~~of ~~Licensed~~which ~~Products~~UNI ~~and~~shall ~~will~~ pay ~~for~~as ~~all~~an ~~costs~~up-front ~~related~~license tofee ~~patent~~($20,000 ~~and~~upon ~~FDA~~signing ~~filings for~~ the ~~Licensed~~agreement ~~Products.~~and ~~Both parties~~$80,000 ~~recognize~~upon ~~the~~commencement ~~need~~of ~~for~~training ~~additional~~UNI ~~development~~personnel ~~and~~at ~~testing~~ADI offacilities) and the ~~Licensed~~remaining ~~Products to obtain FDA Approval~~ of ~~same.~~which, ~~The parties~~UNI shall ~~meet~~pay onin a4 ~~quarterly~~equal ~~basis~~annual toinstallments ~~discuss~~over the ~~Licensed~~next ~~Products~~4 ~~and the best ways to ensure protection of same~~years. ~~GCDx~~The ~~shall pay~~License usAgreement ~~royalties,~~will ~~which~~become ~~shall~~effective ~~be earned only~~ upon ~~actual~~our receipt of ~~payment~~the ofup-front ~~revenue or sublicense~~ license ~~fees and sublicense royalty fees by GCDx, as set forth in the Agreement~~fee.

~~Although~~The ~~GCDx~~agreement ~~will~~covers ~~pay all costs related to developing~~ the ~~Licensed~~following ~~Products~~territories: ~~for~~China, ~~commercial~~Hong ~~applications~~Kong, ~~including~~Malaysia, ~~process~~Singapore, ~~development~~Indonesia, ~~costs~~Thailand, ~~clinical study~~Japan, ~~costs~~India, Turkey and ~~costs~~Australia ~~related to the FDA filing~~ and ~~approval~~New ~~process,~~Zealand. We ~~the~~also ~~parties~~ agreed ~~that~~not ~~GCDx~~to ~~shall~~issue ~~pay~~exclusive usrights ~~$150~~to ~~per~~any ~~hour~~other ~~for any~~person(s) ~~additional~~to ~~services~~sell ~~GCDx~~the ~~requests~~Tests ~~above~~in ~~those~~the ~~services~~covered ~~initially~~territories ~~contemplated~~during tothe ~~carry~~term ~~out~~of ~~this~~the ~~development~~agreement.

~~The~~If ~~Agreement~~we ~~contains non-compete~~become the party to any type of bankruptcy action or proceeding that disrupts our business and ~~confidentiality~~ability ~~terms~~to ~~regarding~~deliver the ~~Licensed~~Tests, ~~Products~~UNI has the right to use, market and sell the ~~latter~~Tests ofand ~~which~~carry ~~expires~~out 5any ~~years~~tasks ~~after~~to do same; provided however, sales made by UNI pursuant thereto, remain subject to the ~~Agreement terminates~~payment of royalty fees.

The Agreement shall ~~be in~~continue ~~effect~~ until the earlier ~~to occur~~ of: ~~(i)~~ expiration of the last patent issued to us for the ~~Licensed Products~~Tests, ~~(ii)~~ when ~~GCDx~~ UNI terminates the ~~Agreement~~agreement by discontinuing the offering of the ~~Licensed Products or the sublicense to do the same~~Tests, ~~as such discontinuance is defined in the Agreement, for a full calendar year - at which time the license rights will by default return to us,~~ or ~~(iii) by us,~~ if ~~GCDx~~UNI does not achieve sales necessary to meet the ~~contractually~~contractual ~~agreed~~minimum toroyalty ~~Minimum~~payments ~~Royalty Payments, as such term is defined in the Agreement,~~ for ~~any~~ two consecutive fiscal quarters. Each ~~Additionally, either~~ party ~~may~~has ~~terminate~~ the ~~Agreement~~right ~~upon 30 days written notice~~ to ~~the~~terminate ~~other party. The terms of~~ the Agreement ~~provide~~in ~~that~~certain ifcircumstances, ~~either~~including ~~party~~a ~~terminates~~material ~~the~~breach ~~Agreement~~under or the Agreement ~~expires~~ ~~due to nonpayment~~ or ~~otherwise,~~following ~~any~~a ~~and~~cure ~~all~~period ~~license~~associated ~~rights~~with ~~will~~a ~~revert~~government ~~back~~imposed toprohibition ~~us.~~against ~~Three months after~~ the ~~date~~sale of ~~reversion, we~~the ~~will~~licensed ~~be entitled to enter new contractual agreements with third parties with regard to such rights~~products.

~~The~~A ~~foregoing~~new ~~document~~independent ~~and~~scientific ~~transaction descriptions~~study ~~above~~published ~~are not~~in ~~complete~~the Oncogenesis, Inflammatory and ~~are~~Parasitic ~~subject~~Tropical Diseases of the Lung edited by Jean-Marie Kayembe, ISBN 978-953-51-0982-2, published February 13, 2013, indicated that Onko-Sure® itself might contribute to confirm tumor diagnosis and ~~qualified~~to inidentify ~~their~~patients ~~entirety~~with byadvanced ~~reference~~lung tocancer, ~~the~~with ~~exhibits attached~~high ~~hereto~~sensitivity (95.8%) and ~~incorporated~~specificity ~~herein~~(91.9%). byThis ~~reference~~new data strengthens our views that Onko-Sure® can be used as a lung cancer screening tool.

~~The~~Section ~~transaction~~5 ~~documents~~- ~~have~~Corporate ~~been~~Governance ~~included to provide investors~~ and security holders with information regarding their respective terms. They are not intended to provide any other financial information about us or our subsidiaries and affiliates. The representations, warranties and covenants contained in the transaction documents were made only for purposes of those agreements and as of specific dates; were solely for the benefit of the parties to such agreements; may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the agreements instead of establishing these matters as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of us or our subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the agreements, which subsequent information may or may not be fully reflected in public disclosures by us.Management

InItem addition to the foregoing, as we have previously disclosed, as a result of our working capital deficiencies, we previously disclosed that we laid off a substantial portion of our work force and are currently operating on a minimal basis with only 2 employees and three former employee consultants5.02 ~~The current focus of our operations is to ensure that our existing Onko~~-~~Sure®~~ ~~customers~~Departure and any future customers are able to place orders and receive kits on a timely basis. We have an Onko-Sure® production continuity arrangement in place with one vendor. At the current time, the Company believes that it does not require any additional staff to perform this limited manufacturing, quality control and selling process. Furthermore, although the upfront licensing fee and potential ongoing licensing fees may help off-set certain of ~~our~~Directors ~~working~~or ~~capital~~Certain ~~deficiencies, it will not be sufficient to allow us to reestablish normal operations at this time.~~Officers

~~Item~~On 9June 4, 2013, Mr.01 ~~Financial~~Michael ~~Statements~~Boswell resigned as a member of our Board of Directors and ~~Exhibits~~our Board of Directors accepted his resignation. Mr. Boswell's resignation did not indicate that his resignation was in connection with any disagreement with the Company pertaining to the Company’s operations, policies or practices. Mr. Boswell resigned to dedicate more of his time to his own business and personal pursuits.

~~(c)~~On ~~Exhibits~~June 7th, 2013, the Board of Directors appointed Mr. Michael Christiansen to fill the vacancy on our Board created by Mr. Boswell's resignation. Mr. Christiansen was formerly the Executive Vice President and Chief Financial Officer of Jameson Stanford Resources Corporation and Bolcán Mining Corporation from May 2012 to November 2012, with his service concluding upon the closing of the merger of the two companies. Prior to joining Bolcán, Mr. Christiansen worked at WestPark Capital from 2007 to 2012 as Managing Director in the Corporate Finance group. Mr. Christiansen has more than fifteen years of investment banking experience, having served previously with Prudential Securities from 1997 to 2001, and with Seidler Amdec Securities and Laffer Associates from 1986 to 1992. His investment banking experience includes public and private equity transactions, mergers and acquisitions, and strategic advisory engagements with clients in consumer, retailing, software and technology industries. As a senior investment banker, he has advised clients on over $1.3 billion in aggregate closed financing transactions. Mr. Christiansen also served as Executive Vice President and Chief Financial Officer of Vizional Technologies, Inc. from 2002 through 2006, and as Executive Vice President and Chief Financial Officer of PortaCom Wireless, Inc. from 1994 to 1996. Mr. Christiansen was awarded an MBA from the University of Southern California and a B.S. degree in corporate finance and economics from Utah State University.

Exhibit No.	Description
10.1	Agreement with Global Cancer Diagnostics, Inc. dated July 13, 2012

Section 8 – Other Events

~~SIGNATURES~~Item 8.01 – Other Events

~~Pursuant~~From an operational perspective, with appropriate capital, we can continue to ~~the~~sell ~~requirements~~and ofship Onko-Sure® test kits to the ~~Securities Exchange~~following ~~Act~~territories: ofKorea, ~~1934~~Turkey, Taiwan, India, Vietnam, and the ~~Registrant~~U.S. ~~has~~Despite ~~duly~~significant ~~caused~~financial ~~this~~hardship, ~~report~~we continue to bemaintain ~~signed~~our offices and FDA approved manufacturing facilities in Tustin, California, relying on ~~its~~selective ~~behalf~~former byemployees that continue to work as consultants. We are also engaged in business discussions with other companies seeking to license or purchase Onko-Sure for various domestic and international territories, although we have not entered into any formal agreements at this time. We are hopeful that if we can complete a sufficient number of these licensing and sales agreements, we will have enough capital to regain compliance with our public filing requirements and to begin to pay down various overdue accounts payable. These agreements may also allow us to restructure or convert to equity our existing notes payable in order to significantly reduce or eliminate a majority of the ~~undersigned~~liabilities ~~hereunto~~on ~~duly~~our ~~authorized~~balance sheet. There can be no guarantee that any new licensing, purchase or restructuring transactions will be completed or that they will provide sufficient capital to carry out our plans.

~~RADIENT PHARMACEUTICALS~~As ~~CORPORATION~~of June 10th 2013, we had approximately 4,508,746,417 shares of common stock issued and outstanding.

By:	/s/ Douglas C. MacLellan
Name:	Douglas C. MacLellan
Title:	Chairman & CEO
Dated: July 17, 2012

Item 9.01 Financial Statements and Exhibits

Exhibit No.		Description
10.1		Agreement with Uni Pharma Co., Ltd. dated June 6, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RADIENT PHARMACEUTICALS CORPORATION

By:	/s/ Douglas C. MacLellan
Name:	Douglas C. MacLellan
Title:	Chairman & CEO

Dated: June 11, 2013

Filing Compare · RADIENT PHARMACEUTICALS Corp